ESTRO 2025 - Abstract Book

S1201

Clinical – Lower GI

ESTRO 2025

Conclusion: After 5-year follow-up, TNT group achieved comparable DFS and improved OS, with no significant differences regarding QoL, suggesting it as a recommended neoadjuvant treatment option for patients with LARC.

Keywords: Rectal cancer, Phase III trial, 5-year outcome

References: 1. Jin, J., et al., Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J Clin Oncol, 2022. 40(15): p. 1681-1692.